Rating History for Novartis (NVS) by Barclays
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 1/6/2026 | Emmanuel Papadakis | Upgrade | Equalweight (Underweight) |
N/A (N/A) |
137.91 (160.12) |
16.1% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 1/6/2026 | Emmanuel Papadakis | Upgrade | Equalweight (Underweight) |
N/A (N/A) |
137.91 (160.12) |
16.1% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||